Although EMP1 is reportedly downregulated in the cancer region as compared with the adjacent normal epithelium at the primary tumor site [29], this molecule has also been proposed as a marker of resistance to cancer therapies and related to poor prognosis [30, 31]. Here, EMP1 is linked to neoplasm.